Switzerland· 61521003
Nulojix 250 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
A belatacept product containing belataceptum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Belatacept is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AA28 (belatacept), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Belatacept · ATC L04AA28
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belatacept costs, country by country.
Normalised to the WHO defined daily dose (12.5 mg), so markets compare like for like.
- Switzerland: $32.75 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Belatacept · price per daily dose (12.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$32.75
The record
At a glance
Swissmedic (Switzerland)- Active substance
- belataceptum
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L04AA28
- ATC class
- Belatacept
- Defined daily dose
- 12.5 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680615210037Durchstf 1 StkCHF 330.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
62 interactions on record for belatacept.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Belatacept · interactions on record
62 records
- 29 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Belatacept in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNULOJIXBristol-Myers Squibb Pharma EEIG, Dublin
- SpainNULOJIX 250 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandNulojixBristol-Myers Squibb Pharma EEIG
- FranceNULOJIX 250 mg, poudre pour solution à diluer pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomNulojix 250mg powder for concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandNULOJIX 250 mg powder for concentrate for solution for infusionBristol-Myers Squibb Pharma EEIG
- IcelandNulojixBristol-Myers Squibb Pharma EEIG*
- NetherlandsNulojix 25 mg/ml, poeder voor concentraat voor oplossing voor infusieBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nulojix
- Liechtenstein · Nulojix
- Norway · Nulojix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/02ce5d42-dc1f-47c4-bcf7-94092a71ad0a GET /v1/drugs/02ce5d42-dc1f-47c4-bcf7-94092a71ad0a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "belataceptum 250 mg",
"valid_from": "2023-11-01",
"limitations": "[{\"description\":\"Zur Prophylaxe einer Transplantatabstossung bei Patienten nach Nierentransplantation mit einer Einleitungstherapie mit einem Interleukin-2 (IL-2)-Rezeptorantagonisten in Kombination mit Mycophenolsäure und Kortikosteroiden.<br>\\nNulojix darf ausschliesslich in Spital- und Dialysezentren unter Aufsicht eines spezialisierten Arztes mit Erfahrung im Bereich der immunsupressiven Therapie und in der Behandlung von Nierentransplantationspatienten verordnet/verabreicht werden.\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2023-11-01\"}]",
"galenic_form": "Trockensub 250 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2023-11-01",
"self_retention_pct": 10
}See everything about belatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.